146 related articles for article (PubMed ID: 35318162)
1. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
3. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.
Gilsenan A; Midkiff K; Harris D; McQuay L; Hunter S; Kellier-Steele N; Andrews E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1616-1626. PubMed ID: 32894794
[TBL] [Abstract][Full Text] [Related]
4. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.
Gilsenan A; Harding A; Kellier-Steele N; Harris D; Midkiff K; Andrews E
Osteoporos Int; 2018 Oct; 29(10):2335-2343. PubMed ID: 29978254
[TBL] [Abstract][Full Text] [Related]
5. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
Krege JH; Gilsenan AW; Komacko JL; Kellier-Steele N
JBMR Plus; 2022 Sep; 6(9):e10665. PubMed ID: 36111201
[TBL] [Abstract][Full Text] [Related]
6. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study.
Gilsenan A; Harris D; Reynolds M; McSorley D; Midkiff K; Jackson L; Muldavin B; Kellier-Steele N; Andrews E
Osteoporos Int; 2021 Apr; 32(4):645-651. PubMed ID: 33151378
[TBL] [Abstract][Full Text] [Related]
7. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
8. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
9. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide in individuals with a prior history of radiation therapy-a case series.
Cheung YM; Hamnvik OR
Arch Osteoporos; 2021 Oct; 16(1):149. PubMed ID: 34608566
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
12. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide for severe osteoporosis.
Cappuzzo KA; Delafuente JC
Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
[TBL] [Abstract][Full Text] [Related]
14. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
15. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
16. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
18. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.
Elraiyah T; Gionfriddo MR; Murad MH
J Clin Epidemiol; 2015 Jun; 68(6):698-702. PubMed ID: 25766055
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
20. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
